Carregant...
Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
The recent introduction of direct oral anticoagulants, including rivaroxaban, dabigatran, apixaban, and edoxaban, for the acute treatment and secondary prevention of venous thromboembolism and in atrial fibrillation has been shown to provide greater clinical benefit than oral vitamin K antagonists....
Guardat en:
| Publicat a: | SAGE Open Med Case Rep |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5768245/ https://ncbi.nlm.nih.gov/pubmed/29348918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050313X17753336 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|